Det primære endepunkt for terapeutisk respons var et sammensat serologisk endepunkt, omfattende suppression af HBV- DNA til < 5 log10 kopier/ ml sammen med enten tab af serum- HBeAg eller normaliseret ALT.
The primary endpoint of therapeutic response was a composite serological endpoint requiring suppression of HBV DNA to < 5 log10 copies/ ml in conjunction with either loss of serum HBeAg or ALT normalised.